WHO-CHOICE Generalized Cost-Effectiveness Analysis (updated methodology)
This method helps countries decide which health interventions give the most health benefit for the money spent. It uses a standardized, large-scale approach to compare many health programs at once, supporting fair and efficient decisions in health planning, especially in low- and middle-income countries.
At a glance
Use when
Conducting strategic priority setting at national or regional levels, especially in resource-constrained settings; comparing a wide range of interventions across disease areas; informing health policy aligned with SDGs
Avoid when
Highly context-specific decisions requiring local cost and effectiveness data; when detailed budget impact analysis is the primary need; when stakeholder values and equity considerations require in-depth qualitative assessment beyond efficiency
Inputs
Epidemiological data, intervention coverage, cost data (unit and program), disability weights, demographic projections, health system constraints
Outputs
Incremental cost-effectiveness ratios (ICERs), health impact estimates (e.g., DALYs averted), resource requirements, scalability assessments
How it works
The WHO-CHOICE Generalized Cost-Effectiveness Analysis (GCEA) is a methodological framework for conducting comparative economic evaluations across a wide range of health interventions. It employs a standardized, regionalized modeling approach to estimate cost-effectiveness ratios, scalability, and health impact under different resource constraints. Updated in 2021, it integrates epidemiological, cost, and intervention data to inform priority setting at the population level, supporting strategic planning toward the Sustainable Development Goals. The method emphasizes generalizability over local specificity, enabling cross-country and cross-intervention comparisons.
- HTA domains
- Clinical Effectiveness, Costs & Economic Evaluation
- Categories
- Cost-effectiveness Modelling
- Assumptions
- Health systems aim to maximize population health; interventions are scalable; cost and effect data are transferable across settings with adjustments; decision makers consider efficiency as one criterion among others
- Strengths
- Enables broad cross-intervention comparisons; supports equity through regional and income-level stratification; uses transparent, standardized methods; designed for low-resource settings; supports strategic priority setting at national and global levels
- Limitations
- Less tailored to local contexts than fully context-specific analyses; relies on modeling assumptions and data extrapolation; may not capture all implementation challenges or local preferences
- Also known as
- WHO-CHOICE GCEA, Generalized Cost-Effectiveness Analysis, WHO CHOICE method
Questions this answers
- › Which health interventions provide the greatest health gains per unit of cost?
- › How can health resources be allocated efficiently across different diseases and interventions?
- › What is the potential health impact of scaling up specific interventions?
- › How do cost-effectiveness results vary across different epidemiological and economic contexts?
- › Which interventions represent good value for money in achieving health-related SDGs?
- › What are the opportunity costs of choosing one intervention over another?
References & sources
Similar by meaning
- Generalized Cost-Effectiveness Analysis (GCEA / WHO-CHOICE)
- Generalized Risk-Adjusted Cost-Effectiveness (GRACE)
- Evaluation of Intervention Impact on Health Inequality for Resource Allocation
- Cost-Effective but Unaffordable Paradox / Nonmarginal Health Opportunity Cost Method
- Efficiency frontier approach (IQWiG cost-benefit assessment)
Beta record. Generated from the primary source via AI extraction and independent audit, pending final human review.